SCHEMBL6715324

SCHEMBL6715324

CCOC(=O)C=Cc1ccc(C(=O)N(CCc2cccc(OC)c2)c2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.48
PTGES O14684 1/20 0.48
TRPM8 Q7Z2W7 2/20 0.48
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HTT P42858 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
NR1H4 Q96RI1 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
APP P05067 1/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC2 Q92769 2/20 0.44
ACHE P22303 1/20 0.43
MAOB P27338 1/20 0.43
PTGS2 P35354 1/20 0.42
TTR P02766 1/20 0.42
LPAR1 Q92633 1/20 0.42
LPAR5 Q9H1C0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715318 1.00 ALOX5 (0.48) ALOX5PTGESTRPM8KDM4EALDH1A1
SCHEMBL6715386 0.83 NPC1 (0.61) ALOX5PTGESKDM4ENPC1RAB9A
SCHEMBL6715335 0.83 PTGES (0.60) ALOX5PTGESNPC1RAB9AACHE
SCHEMBL6715294 0.80 PTGES (0.57) ALOX5PTGESNPC1RAB9AMEN1
SCHEMBL6719063 0.80 PTGES (0.57) ALOX5PTGESKDM4ENPC1RAB9A
SCHEMBL6713540 0.78 PTGES (0.54) ALOX5PTGESKDM4EALDH1A1NPC1
SCHEMBL6716749 0.78 TRPM8 (0.48) TRPM8HTTNPC1RAB9ANR1H4
SCHEMBL16924140 0.77 TRPM8 (0.55) ALOX5PTGESTRPM8KDM4EALDH1A1
SCHEMBL6716683 0.76 ALOX5 (0.54) ALOX5PTGESHDAC1HDAC2LPAR1
SCHEMBL22423058 0.75 ALOX5 (0.75) ALOX5KDM4EALDH1A1HTTAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040192685-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists CAMERON KIMBERLY O (US) 2004-09-30 US disclosed
US-20030220494-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists CAMERON KIMBERLY O (US) 2003-11-27 US disclosed
US-6608203-B2 Devoid of unwanted side effects PFIZER INC. 2003-08-19 US disclosed
US-20010039285-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists CAMERON KIMBERLY O (US) 2001-11-08 US disclosed
EP-1113007-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists PFIZER INC. (US) 2001-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039285-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists GPER1, ESR1, ESR2 ALOX5 644/4885PTGES 181/4885TRPM8 905/4885
US-20030220494-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists GPER1, ESR1, ESR2 ALOX5 644/4885PTGES 181/4885TRPM8 905/4885
US-20040192685-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists GPER1, ESR1, ESR2 ALOX5 644/4885PTGES 181/4885TRPM8 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.